09:19:12 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-21 Bokslutskommuniké 2024
2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 X-dag ordinarie utdelning ABLI 0.00 SEK
2024-05-23 Kvartalsrapport 2024-Q1
2024-05-23 Årsstämma 2024
2024-03-26 Extra Bolagsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-11-17 Kvartalsrapport 2023-Q3
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-23 Kvartalsrapport 2023-Q1
2023-05-08 X-dag ordinarie utdelning ABLI 0.00 SEK
2023-05-05 Årsstämma 2023
2023-03-08 Extra Bolagsstämma 2022
2023-02-24 Bokslutskommuniké 2022
2022-11-22 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-31 Kvartalsrapport 2022-Q1
2022-05-20 Årsstämma 2022
2022-04-28 X-dag ordinarie utdelning ABLI 0.00 SEK
2022-02-22 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 X-dag ordinarie utdelning ABLI 0.00 SEK
2021-05-20 Årsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-04-29 Extra Bolagsstämma 2021
2021-02-19 Bokslutskommuniké 2020
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-22 X-dag ordinarie utdelning ABLI 0.00 SEK
2020-05-20 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1
2020-03-17 Extra Bolagsstämma 2020
2020-02-19 Bokslutskommuniké 2019
2019-11-20 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-21 Kvartalsrapport 2019-Q1
2019-04-26 X-dag ordinarie utdelning ABLI 0.00 SEK
2019-04-25 Årsstämma 2019
2019-02-28 Bokslutskommuniké 2018
2019-01-17 Extra Bolagsstämma 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-22 Kvartalsrapport 2018-Q1
2018-04-30 X-dag ordinarie utdelning ABLI 0.00 SEK
2018-04-27 Årsstämma 2018
2018-02-20 Bokslutskommuniké 2017
2017-11-21 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2
2017-05-18 Kvartalsrapport 2017-Q1
2017-04-28 X-dag ordinarie utdelning ABLI 0.00 SEK
2017-04-27 Årsstämma 2017
2017-02-21 Bokslutskommuniké 2016
2016-11-22 Kvartalsrapport 2016-Q3
2016-08-18 Kvartalsrapport 2016-Q2
2016-05-31 Kvartalsrapport 2016-Q1
2016-04-29 X-dag ordinarie utdelning ABLI 0.00 SEK
2016-04-28 Årsstämma 2016
2016-03-31 Extra Bolagsstämma 2016
2016-02-19 Bokslutskommuniké 2015
2015-11-18 Kvartalsrapport 2015-Q3
2015-08-19 Kvartalsrapport 2015-Q2
2015-05-20 Kvartalsrapport 2015-Q1
2015-03-31 X-dag ordinarie utdelning ABLI 0.00 SEK
2015-03-30 Årsstämma 2015
2015-02-18 Bokslutskommuniké 2014
2014-11-19 Kvartalsrapport 2014-Q3
2014-08-20 Kvartalsrapport 2014-Q2
2014-05-12 X-dag ordinarie utdelning ABLI 0.00 SEK
2014-05-09 Kvartalsrapport 2014-Q1
2014-05-09 Årsstämma 2014
2014-02-19 Bokslutskommuniké 2013
2014-01-21 Analytiker möte 2014
2013-12-13 Extra Bolagsstämma 2013
2013-11-20 Kvartalsrapport 2013-Q3
2013-08-23 Kvartalsrapport 2013-Q2
2013-05-24 Kvartalsrapport 2013-Q1
2013-03-11 X-dag ordinarie utdelning ABLI 0.00 SEK
2013-03-08 Årsstämma 2013
2013-02-05 Bokslutskommuniké 2012
2012-10-15 Kvartalsrapport 2012-Q3
2012-08-21 Kvartalsrapport 2012-Q2
2012-06-11 X-dag ordinarie utdelning ABLI 0.00 SEK
2012-06-08 Årsstämma 2012
2012-05-31 Kvartalsrapport 2012-Q1
2012-04-02 Extra Bolagsstämma 2012
2012-02-21 Bokslutskommuniké 2011
2011-11-22 Kvartalsrapport 2011-Q3
2011-08-23 Kvartalsrapport 2011-Q2
2011-06-10 Årsstämma 2011
2011-05-17 Kvartalsrapport 2011-Q1
2011-02-22 Bokslutskommuniké 2010
2010-11-18 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-06-11 X-dag ordinarie utdelning ABLI 0.00 SEK
2010-05-20 Kvartalsrapport 2010-Q1
2009-11-19 Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Abliva är ett läkemedelsbolag. Bolaget utvecklar läkemedel för behandling av primära mitokondriella sjukdomar. Dessa medfödda, sällsynta och ofta mycket svåra sjukdomar uppstår då cellens energiförsörjare, mitokondrierna, inte fungerar som de ska. Portföljen omfattar projekt i olika skeden och sträcker sig från tidig upptäcktsfas till klinisk fas. Bolaget gick tidigare under namnet NeuroVive Pharmaceutical.
2024-04-25 16:05:00

THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER COUNTRY WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE PREPARED OR REGISTERED OR REQUIRE ANY OTHER ACTIONS TO BE TAKEN, IN ADDITION TO THE REQUIREMENTS UNDER SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

Abliva AB (Nasdaq Stockholm: ABLI) ("Abliva" or the "Company") has today, based on the authorization from the extraordinary general meeting on 26 March 2024, resolved on a directed issue of 5,003,783 shares to guarantors who entered into guarantee commitments in connection with the rights issue of shares that was announced on February 22, 2024 (the "Rights Issue") and who have chosen to receive guarantee compensation in the form of newly issued shares in the Company (the "Compensation Issue"). The subscription price in the Compensation Issue amounts to SEK 0.16 per share, which corresponds to the subscription price in the Rights Issue. Payment is made by offsetting the claim of guarantee compensation.

In connection with the publication of the Rights Issue, it was communicated that the Rights Issue was covered by guarantee commitments of a total amount of approximately SEK 23.5 million. In accordance with the guarantee undertakings, guarantors were entitled to guarantee compensation corresponding to twelve (12) percent of the guaranteed amount in cash or fourteen (14) percent in shares. The Board of Directors has decided that payment shall be made by offsetting the guarantors' claims on the Company, in relation to guarantors who have chosen to receive the guarantee compensation in the form of newly issued shares, amounting to a total of approximately SEK 0.8 million.

Abliva's Board of Directors has therefore today, based on the authorization from the extraordinary general meeting on 26 March 2024, resolved on the Compensation Issue of a total of 5,003,783 shares. The purpose of the directed Compensation Issue and the reason for the deviation from the shareholders’ preferential rights is to fulfill the Company's obligations towards the guarantors in accordance with entered guarantee undertakings. In addition, the Board of Directors believes that it is both beneficial for the Company's financial position and in the shareholders’ interest to use the opportunity to pay the guarantee compensation in the form of shares instead of cash payment. The payment of the guarantee compensation in shares releases funds that will strengthen the Company's working capital and also will allow the Company to use a larger part of the net proceeds from the Rights Issue as described in the prospectus that was published on 27 March 2024.

The subscription price in the Compensation Issue amounts to SEK 0.16 per share, which corresponds the subscription price in the Rights Issue. The subscription price in the directed Compensation Issue was negotiated in connection with entering of the guarantee undertakings and in connection with a directed convertible issue that was resolved by the Board of Directors on 22 February 2024, which was determined together with the financial advisor and after an analysis of the market situation. The Board of Directors’ assessment is therefore that the subscription price, as well as other terms in the directed Compensation Issue, is considered market value.

The Compensation Issue increases the number of shares in Abliva by 5,003,783, from 1,344,380,753 to 1,349,384,536 calculated after registration of the shares subscribed for in the Rights Issue. The share capital thereby increases by approximately SEK 250,189.15, from approximately SEK 67,219,037.65 to approximately SEK 67,469,226.80 calculated after registration of the shares subscribed for in the Rights Issue. The Compensation Issue thus entails a dilutive effect on the Company's shares of approximately 0.4 percent.

“We are happy to learn of the decision by both old and new shareholders to take their underwriting fee in the form of shares, providing an additional sign of confidence in the company as we approach a major milestone this summer,“ said Ellen Donnelly, CEO.

Advisors
Hagberg & Aneborn Fondkommission AB is the sole global coordinator and bookrunner in connection with the Rights Issue. Cirio Advokatbyrå AB is legal advisor to Abliva in connection with the Rights Issue.